Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors:… Recruiting

2024-519505-35-00 hepatocellulaR carcinoma 5 2026-02-02
A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA … Recruiting

2025-523273-41-00 Metastatic castration-resistant prostate cancer 7 2026-01-30
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin… Recruiting

2025-521606-18-00 Ovarian Cancer 4 2026-01-29
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Phase 1 Study for ZW251 in Participants with Solid Tumors. Recruiting

2025-523088-39-00 Advanced Solid Tumors 1 2026-01-28
A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting

2025-521043-20-00 Neuroendocrine tumors 10 2026-01-27
A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment pumit… Recruiting

2025-521768-36-00 Metastatic colorectal cancer 9 2026-01-27
INTERACT-FAPI Recruiting

2024-520037-76-00 Peritoneal metastases 3 2026-01-27
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors Recruiting

2025-521828-30-00 Advanced Solid Tumors 9 2026-01-27
SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions Recruiting

2025-522962-58-00 Renal cell carcinom 4 2026-01-26
Is magnesium sulfate an alternative with an analgesic and safety profile equivalent to dexmedetomidine as an adjuvant to ropivacaine in erec… Recruiting

2025-523152-31-00 Breast cancer 6 2026-01-26
A Phase 1-2 Master Protocol to Study Intravenous ATTR-01 in Adult Participants with Select Epithelial Solid Tumours Under Multiple Sub-proto… Recruiting

2024-516722-59-00 Select Epithelial Solid Tumours 7 2026-01-23
A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with o… Recruiting

2025-522731-34-00 Ovarian cancer Primary peritoneal cancer Fallopian tube 3 2026-01-23
Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) Recruiting

2024-514400-14-00 liver transplanted patients with advanced hepatocellula 4 2026-01-23
Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting

2025-522090-11-00 Relapsed or Refractory Multiple Myeloma (RRMM) 9 2026-01-22
Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting

2024-515023-11-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2026-01-22
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onc… Recruiting

2025-523620-44-02 non small cell lung cancer (NSCLC) 6 2026-01-20
IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator… Recruiting

2025-522500-24-00 Head and Neck squamous cell carcinoma 5 2026-01-20
Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans… Recruiting

2023-507879-21-00 AML and MDS undergoing allogeneic Transplantation 4 2026-01-19
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma Recruiting

2025-522307-14-00 Melanoma 2 2026-01-19
A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting

2025-521441-24-00 Advanced or Metastatic Solid Tumors 7 2026-01-19